Request Sample
Request Methodology
Description
Thrombectomy Devices Market size was valued at USD 1,682.07 million in 2021, growing at a CAGR of 5.8% during the forecast period 2022-2028. A surgical thrombectomy occurs when a blood clot is removed from a vein or artery. Surgery is performed when blood coagulates and clusters in the blood vessels, forming a blood clot. During surgery, thrombectomy instruments are used to make an incision in a blood vessel. Blood flow is restored once the clot is removed and the blood artery is healed. Thrombectomy devices are the most widely used for thrombectomy treatments when compared to other methods. Increasing prevalence of CVDs and neurological illnesses, technological advancements, government initiatives aimed at disease prevention, and favourable medical reimbursement situations are all driving the Thrombectomy Devices market in healthcare forward. Thrombectomy systems are used in a number of therapies where clots must be removed in order to provide effective treatment and preserve patients’ lives. Acute myocardial infarction (AMI), peripheral arterial disease (PAD), deep vein thrombosis (DVT), pulmonary embolism (PE), and neurovascular operations can all benefit from the thrombectomy system’s versatility. In addition, the market share is predicted to grow due to an increase in demand for less invasive surgeries and an ageing population. Furthermore, the rising frequency of cardiac disorders, combined with changing lifestyles, is likely to propel the market forward.
Key Development:
In Oct 2015, Penumbra, Inc. has launched Separator 3D, an advanced thrombectomy device to treat cerebral occlusions that causes ischemic stroke
